Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary PRINT technology to transform the lives of patients. Currently, Liquidia is focused on the development of two product candidates using its PRINTÂŽ particle engineering platform: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Source
No articles found.
Connectyx Technologies Holdings Group, Inc. provides products in the healthcare ma...
Connectyx Technologies Holdings Group, Inc. pro...
CytomX Therapeutics develops Probody⢠therapeutics for the treatment of cancer. ...
CytomX Therapeutics develops Probody⢠therape...
ViewRayÂŽ Inc., (NASDAQ:VRAY), designs, manufactures and markets MRIdianÂŽ the wor...
ViewRayÂŽ Inc., (NASDAQ:VRAY), designs, manufac...
United-Guardian, Inc. ("United") is a diversified company that conducts research, ...
United-Guardian, Inc. ("United") is a diversifi...
Blueprint Medicines is a precision therapy company striving to improve human healt...
Blueprint Medicines is a precision therapy comp...
PhorMed is a clinical stage biopharmaceutical company located in Beverly Hills Cal...
PhorMed is a clinical stage biopharmaceutical c...
CHF Solutions is focused on improving the quality of life for patients suffering f...
CHF Solutions is focused on improving the quali...
Correvio has two marketed, in-hospital, cardiology products: BRINAVESSÂŽ (vernakal...
Correvio has two marketed, in-hospital, cardiol...
The Medicines Company is a biopharmaceutical company driven by an overriding purpo...
The Medicines Company is a biopharmaceutical co...
We are a leading science and technology company that delivers life-transforming me...
We are a leading science and technology company...
Join the National Investor Network and get the latest information with your interests in mind.